However, recent studies have displayed a synthetic lethal interaction of SHOC2 depletion, but not MRAS, with MEK inhibitors in KRAS-mutant pancreatic or lung cancer cell lines18. This evidence concerns the gene SHOC2 and lung carcinoma.